Physician profile
Robert R Daiber
NPI 1922147818
$1,179.57
in general payments reported to CMS, 2019-2025
14 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2021: $45.98 · 2023: $57.94 · 2024: $464 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.55 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.16 | 2023-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $130.89 | 2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $122.33 | 2024-2025 | Fanapt, Hetlioz |
| Braeburn INC. | $106.61 | 2024-2025 | Brixadi |
| Indivior INC. | $85.10 | 2024-2025 | Sublocade |
| Alkermes, INC. | $70.02 | 2024-2025 | Aristada, Vivitrol, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $38.50 | 2023-2025 | Nuedexta, Rexulti |
| Amgen INC. | $36.26 | 2021-2025 | Evenity |
| Lundbeck LLC | $33.71 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $23.29 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.55 | 2025 | Caplyta |
| Acadia Pharmaceuticals INC | $11.55 | 2019 | |
| Sumitomo Pharma America, INC. | $5.60 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Daiber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.